Harrow: VEVYE Excluded from Part D Plans in 2025, Conflicting with Company’s Claims of ‘Market Access Win’ in Medicare

Published on Jan 14, 2025

VEVYE, a dry eye disease drug marketed by Harrow (HROW), doesn’t appear to be covered by any Medicare Part D prescription drug plans in 2025, despite the ophthalmic health care company advertising that the drug was slated to get coverage in that market, a Capitol Forum investigation has found.

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2025 The Capitol Forum. All Rights Reserved.